Lease Agreement between TNO and ProQR Therapeutics I B.V. Zernikedreef 9 Leiden Period: 1 January 2016 to 31 December 2020 inclusiveLease Agreement • March 31st, 2017 • ProQR Therapeutics N.V. • Pharmaceutical preparations
This model may only be referred to and utilised if the text that has been filled in, added or modified is clearly recognisable as such. Any additions and amendments should preferably be incorporated under the heading ‘Special Provisions’. The Council accepts no responsibility for adverse consequences arising from the use of the text of the model.
Amendment Number 4 To Exclusive Patent License Agreement MGH Agreement Number: A212814.04 MGH Case Number: 2562Exclusive Patent License Agreement • March 31st, 2017 • ProQR Therapeutics N.V. • Pharmaceutical preparations
This Amendment to the Exclusive Patent License Agreement (“Fourth Amendment”) is made as of September, 28, 2016 (“Fourth Amendment Effective Date”) by and between ProQR Therapeutics III B.V., a public company organized and existing under the laws of The Netherlands and having a place of business at Zernikedreef 9, 2333CK Leiden, The Netherlands (“Company”) and The General Hospital Corporation, d/b/a Massachusetts General Hospital, a not-for-profit Massachusetts corporation, with a principal place of business at 55 Fruit Street, Boston, Massachusetts 02114 (“Hospital”), each referred to herein individually as “Party’’ and collectively as “Parties.”
LICENSE AGREEMENT between Radboudumc as Licensor, and ProQR Therapeutics B.V. as Licensee regarding antisense oligonucleotide-based therapy for CEP290-associated LCA CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “***”. A...License Agreement • March 31st, 2017 • ProQR Therapeutics N.V. • Pharmaceutical preparations
PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; *** DENOTES OMISSIONS
